Physician profile
Doris Yoder
NPI 1730668328
$18,140.03
in general payments reported to CMS, 2019-2025
60 companies · $3,214 in 2025
The $3,214 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,962 · 2022: $4,834 · 2023: $3,461 · 2024: $3,669 · 2025: $3,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $42.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,301.66 |
| Education | $42.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,862.48 | 2021-2025 | |
| Medtronic, INC. | $1,752.74 | 2021-2023 | Sensight |
| Neurocrine Biosciences, INC. | $1,168.22 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $931.47 | 2022-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Eisai INC. | $849.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $757.69 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $678.84 | 2021-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $663.69 | 2021-2023 | |
| Biogen, INC. | $634.30 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Neurelis, INC. | $587.44 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $553.01 | 2021-2024 | Austedo, Austedo Xr |
| Sk Life Science, INC. | $538.59 | 2021-2025 | |
| Lilly USA, LLC | $428.46 | 2021-2025 | Kisunla, Mounjaro, Reyvow |
| Ani Pharmaceuticals, INC. | $378.35 | 2024-2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $296.60 | 2021-2025 | Wavewriter Alpha Prime 16 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $273.48 | 2021-2025 | Nuplazid |
| Catalyst Pharmaceuticals, INC. | $273.01 | 2023-2025 | Firdapse, Fycompa |
| Mallinckrodt Hospital Products INC. | $272.51 | 2023-2025 | Acthar |
| Banner Life Sciences, LLC | $260.86 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $253.62 | 2023-2024 | Aptiom |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $249.72 | 2022-2024 | Caplyta |
| Amneal Pharmaceuticals LLC | $240.39 | 2021-2025 | Rytary, Crexont |
| Allergan, INC. | $226.89 | 2021-2022 | |
| Amgen INC. | $224.76 | 2021-2025 | Uplizna |
| Lundbeck LLC | $218.71 | 2022-2025 | Rexulti, Vyepti |
| Argenx US, INC. | $190.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Pharmaceuticals, INC | $189.50 | 2022-2024 | Spravato |
| Genentech USA, INC. | $187.28 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Pfizer INC. | $185.84 | 2021-2025 | |
| Grifols USA, LLC | $174.56 | 2023-2024 | Gamunex-C |
| Tg Therapeutics, INC. | $172.24 | 2025 | |
| Horizon Therapeutics Plc | $129.59 | 2021-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $116.49 | 2022 | |
| Acorda Therapeutics, INC | $111.89 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $93.67 | 2021 | |
| Upsher-Smith Laboratories LLC | $75.24 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $73.73 | 2025 | Xeomin, Inbrija, Ampyra |
| Corium, LLC | $73.50 | 2022-2023 | Adlarity |
| Travere Therapeutics, INC. | $61.98 | 2022-2023 | Cholbam |
| Biohaven Pharmaceuticals, INC. | $53.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $51.96 | 2024-2025 | Rexulti |
| Tanabe Pharma America, INC. | $49.64 | 2022-2023 | |
| Averitas Pharma INC. | $49.13 | 2024-2025 | Qutenza |
| Emd Serono, INC. | $48.13 | 2023-2024 | Mavenclad |
| Jazz Pharmaceuticals INC. | $46.32 | 2023-2024 | |
| Kyowa Kirin, INC. | $44.77 | 2021-2024 | Nourianz |
| Abbott Laboratories | $44.37 | 2021 | |
| Greenwich Biosciences, INC. | $40.63 | 2021 | |
| Electromed, INC. | $40.59 | 2021-2023 | Smartvest |
| Harmony Biosciences LLC | $32.84 | 2022-2023 | Wakix |
| Livanova USA, INC. | $32.64 | 2022 | |
| Alnylam Pharmaceuticals INC. | $30.64 | 2022-2023 | Amvuttra |
| Nevro Corp. | $29.92 | 2022-2023 | Senza |
| Sunovion Pharmaceuticals INC. | $25.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.92 | 2021 | |
| Csl Behring | $21.78 | 2025 | Hizentra |
| Aquestive Therapeutics, INC. | $17.17 | 2022 | |
| Neuronetics, INC. | $16.40 | 2024 | Neurostar Tms Therapy System |
| Mdd US Operations, LLC | $15.77 | 2025 | |
| Axsome Therapeutics, INC. | $13.70 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.